Literature DB >> 18048579

Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein.

C Avignolo1, L Bagnasco, B Biasotti, A Melchiori, V Tomati, I Bauer, A Salis, L Chiossone, M C Mingari, P Orecchia, B Carnemolla, D Neri, L Zardi, S Parodi.   

Abstract

We constructed a single-chain variable fragment miniantibody (G11-scFv) directed toward the transactivation domain of c-Myc, which is fused with the internalization domain Int of Antennapedia at its carboxyl terminus (a cargo-carrier construct). In ELISA experiments, an EC(50) for binding saturation was achieved at concentrations of G11-scFv-Int(-) of approximately 10(-8) M. Internalization of a fluoresceinated Fl-G11-scFv-Int(+) construct was observed in intact human cultured cells with confocal microscopy. After 5 h of incubation in medium containing 1 microM Fl-G11-scFv-Int(+) or Fl-G11-scFv-Int(-), fluorescence intensity was determined in individual cells, both for cytoplasmic and nuclear compartments: concentration levels of Fl-G11-scFv-Int(+), relative to the extracellular culture medium concentration, were 4-5 times higher in the cytoplasm, 7-8 times higher in the nucleus, and 10 times higher in the nucleoli. In the same experimental conditions, the Fl-G11-scFv-Int(-) construct was 3-4 times more concentrated outside of the cells than inside. Cell membranes kept their integrity after 5 h of incubation. The antiproliferative activity of our miniantibody was studied on HCT116 cells. Incubation with 4 microM G11-scFv-Int(+) for 4 days induced very significant statistical and biological growth inhibition, whereas Int alone was completely inactive. Miniantibodies capable of penetrating cell membranes dramatically broaden the potential for innovative therapeutic agents and attack of new targets.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18048579     DOI: 10.1096/fj.07-8865com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  7 in total

Review 1.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

2.  A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.

Authors:  Alessandra Villa; Valeria Lovato; Emil Bujak; Sarah Wulhfard; Nadine Pasche; Dario Neri
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

3.  A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells.

Authors:  Dong-Ki Choi; Jeomil Bae; Seung-Min Shin; Ju-Yeon Shin; Sunghoon Kim; Yong-Sung Kim
Journal:  MAbs       Date:  2014       Impact factor: 5.857

4.  Molecular imaging of Bcr-Abl phosphokinase in a xenograft model.

Authors:  Ji Yuan Wu; David J Yang; Laura S Angelo; Saady Kohanim; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2009-03-03       Impact factor: 6.261

5.  A peptide tag-specific nanobody enables high-quality labeling for dSTORM imaging.

Authors:  David Virant; Bjoern Traenkle; Julia Maier; Philipp D Kaiser; Mona Bodenhöfer; Christian Schmees; Ilijana Vojnovic; Borbála Pisak-Lukáts; Ulrike Endesfelder; Ulrich Rothbauer
Journal:  Nat Commun       Date:  2018-03-02       Impact factor: 14.919

Review 6.  Targeted Intracellular Delivery of Antibodies: The State of the Art.

Authors:  Tatiana A Slastnikova; A V Ulasov; A A Rosenkranz; A S Sobolev
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

Review 7.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.

Authors:  Janusz Wesolowski; Vanina Alzogaray; Jan Reyelt; Mandy Unger; Karla Juarez; Mariela Urrutia; Ana Cauerhff; Welbeck Danquah; Björn Rissiek; Felix Scheuplein; Nicole Schwarz; Sahil Adriouch; Olivier Boyer; Michel Seman; Alexei Licea; David V Serreze; Fernando A Goldbaum; Friedrich Haag; Friedrich Koch-Nolte
Journal:  Med Microbiol Immunol       Date:  2009-06-16       Impact factor: 3.402

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.